Combination therapy: Histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer

Cancer Letters

Volumn 329, Issue 1, 2013, Pages 1-8

  Diyabalanage, Himashinie V K ^a   Granda, Michael L ^a   Hooker, Jacob M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cancer; Chemotherapy; Cisplatin; Combination therapy; HDAC inhibitor; Histone deacetylase; Platinum drug

Indexed keywords

ABEXINOSTAT; ANTINEOPLASTIC AGENT; BELINOSTAT; CAPECITABINE; CARBOPLATIN; CISPLATIN; CUDC 101; ENTINOSTAT; ETOPOSIDE; GEMCITABINE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDRALAZINE; HYDROLASE INHIBITOR; ISOTRETINOIN; JNJ 16241199; MOCETINOSTAT; PACLITAXEL; PANOBINOSTAT; PEMETREXED; PLATINUM COMPLEX; R 306465; ROMIDEPSIN; TACEDINALINE; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; B CELL LYMPHOMA; BIPOLAR MANIA; BLOOD TOXICITY; BRAIN TUMOR; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CENTRAL NERVOUS SYSTEM TUMOR; CHEMOSENSITIZATION; CLASSICAL HODGKIN LYMPHOMA; CLINICAL EFFECTIVENESS; CONCENTRATION RESPONSE; CUTANEOUS T CELL LYMPHOMA; DNA BINDING; DNA DAMAGE; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME INHIBITION; EPILEPSY; GLIOBLASTOMA; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEMATOLOGIC MALIGNANCY; HUMAN; INOPERABLE CANCER; LEUKEMIA; LIVER CELL CARCINOMA; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MESOTHELIOMA; METASTASIS; MOUTH SQUAMOUS CELL CARCINOMA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; NONHUMAN; OTOTOXICITY; OVARY CANCER; PERIPHERAL T CELL LYMPHOMA; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENT CANCER; SHORT SURVEY; SOFT TISSUE SARCOMA; SOLID TUMOR; STOMACH CANCER; SYSTEMIC DISEASE; T CELL LYMPHOMA; THROMBOCYTE DISORDER; TREATMENT DURATION; UTERINE CERVIX CANCER;

EID: 84871720629     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.09.018     Document Type: Review

References (120)

1. Alberghina L., Chiaradonna F., Vanoni M. Systems biology and the molecular circuits of cancer. Chembiochem 2004, 5:1322-1333.
2. Fearon E.R. Human cancer syndromes: clues to the origin and nature of cancer. Science 1997, 278:1043-1050.
3. Vogelstein B., Kinzler K.W. Cancer genes and the pathways they control. Nature Medicine 2004, 10:789-799.
4. Li E. Chromatin modification and epigenetic reprogramming in mammalian development. Nature Reviews Genetics 2002, 3:662-673.
5. Jaenisch R., Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nature Genetics 2003, 33:245-254.
6. Sharma S., Kelly T.K., Jones P.A. Epigenetics in cancer. Carcinogenesis 2010, 31:27-36.
7. Sawan C., Vaissière T., Murr R., Herceg Z. Epigenetic drivers and genetic passengers on the road to cancer. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 2008, 642:1-13.
8. Feinberg A.P., Tycko B. The history of cancer epigenetics. Nature Reviews Cancer 2004, 4:143-153.
9. Laird P.W. Cancer epigenetics. Human Molecular Genetics 2005, 14:R65-R76.
10. Rodenhiser D., Mann M. Epigenetics and human disease: translating basic biology into clinical applications. Canadian Medical Association Journal 2006, 174:341-348.
11. Grayson D.R., Kundakovic M., Sharma R.P. Is there a future for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders?. Molecular Pharmacology 2010, 77:126-135.
12. Gray S.G. Epigenetic treatment of neurological disease. Epigenomics 2011, 3:431-450.
13. DeVita V.T., Chu E. A history of cancer chemotherapy. Cancer Research 2008, 68:8643-8653.
14. Chabner B.A., Roberts T.G. Chemotherapy and the war on cancer. Nature Reviews Cancer 2005, 5:65-72.
15. Olszewski U., Hamilton G. A better platinum-based anticancer drug yet to come?. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry) 2010, 10:293-301.
16. Sherman S.E., Lippard S.J. Structural aspects of platinum anticancer drug interactions with DNA. Chemical Reviews 1987, 87:1153-1181.
17. Galluzzi L., Senovilla L., Vitale I., Michels J., Martins I., Kepp O., Castedo M., Kroemer G. Molecular mechanisms of cisplatin resistance. Oncogene 2012, 31:1869-1883.
18. Mann B.S., Johnson J.R., Cohen M.H., Justice R., Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. The Oncologist 2007, 12:1247-1252.
19. Lopez G., Liu J., Ren W., Wei W., Wang S., Lahat G., Zhu Q.S., Bornmann W.G., McConkey D.J., Pollock R.E. Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma. Clinical Cancer Research 2009, 15:3472-3483.
20. Furumai R., Matsuyama A., Kobashi N., Lee K.H., Nishiyama M., Nakajima H., Tanaka A., Komatsu Y., Nishino N., Yoshida M. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Research 2002, 62:4916-4921.
21. Suzuki M.M., Bird A. DNA methylation landscapes: provocative insights from epigenomics. Nature Reviews Genetics 2008, 9:465-476.
22. Kim M.S., Kwon H.J., Lee Y.M., Baek J.H., Jang J.E., Lee S.W., Moon E.J., Kim H.S., Lee S.K., Young H. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nature Medicine 2001, 7:437-443.
23. Yoo C.B., Jones P.A. Epigenetic therapy of cancer: past, present and future. Nature Reviews Drug Discovery 2006, 5:37-50.
24. Sigalotti L., Fratta E., Coral S., Cortini E., Covre A., Nicolay H.J.M., Anzalone L., Pezzani L., Di Giacomo A.M., Fonsatti E. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications. Journal of Cellular Physiology 2007, 212:330-344.
25. Papi A., Ferreri A.M., Rocchi P., Guerra F., Orlandi M. Epigenetic modifiers as anticancer drugs: effectiveness of valproic acid in neural crest-derived tumor cells. Anticancer Research 2010, 30:535-540.
26. Balch C., Fang F., Matei D.E., Huang T.H.M., Nephew K.P. Minireview: epigenetic changes in ovarian cancer. Endocrinology 2009, 150:4003-4011.
27. Strahl B.D., Allis C.D. The language of covalent histone modifications. Nature 2000, 403:41-45.
28. Agalioti T., Chen G., Thanos D. Deciphering the transcriptional histone acetylation code for a human gene. Cell 2002, 111:381-392.
29. Ellis L., Atadja P.W., Johnstone R.W. Epigenetics in cancer: targeting chromatin modifications. Molecular Cancer Therapeutics 2009, 8:1409-1420.
30. Hendrich B., Bickmore W. Human diseases with underlying defects in chromatin structure and modification. Human Molecular Genetics 2001, 10:2233-2242.
31. DeVane C. Pharmacokinetics, drug interactions, and tolerability of valproate. Psychopharmacology Bulletin 2003, 37:25-42.
32. Dinarello C.A., Fossati G., Mascagni P. Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer. Molecular Medicine 2011, 17:333-352.
33. Wightman F., Ellenberg P., Churchill M., Lewin S.R. HDAC inhibitors in HIV. Immunology and Cell Biology 2012, 90:47-54.
34. Ververis K., Karagiannis T.C. Overview of the classical histone deacetylase enzymes and histone deacetylase inhibitors. ISRN Cell Biology 2012, 2012:1-12.
35. Touma S.E., Goldberg J.S., Moench P., Guo X., Tickoo S.K., Gudas L.J., Nanus D.M. Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model. Clinical Cancer Research 2005, 11:3558-3566.
36. Kwa F.A.A., Balcerczyk A., Licciardi P., El-Osta A., Karagiannis T.C. Chromatin modifying agents-the cutting edge of anticancer therapy. Drug Discovery Today 2011, 16:543-547.
37. Bots M., Johnstone R.W. Rational combinations using HDAC inhibitors. Clinical Cancer Research 2009, 15:3970-3977.
38. Sawyers C. Targeted cancer therapy. Nature 2004, 432:294-297.
39. Marks P.A., Rifkind R.A., Richon V.M., Breslow R., Miller T., Kelly W.K. Histone deacetylases and cancer: causes and therapies. Nature Reviews Cancer 2001, 1:194-202.
40. Van Lint C., Emiliani S., Verdin E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expression 1996, 5:245-253.
41. Kim Y.B., Ki S.W., Yoshida M., Horinouchi S. Mechanism of cell cycle arrest caused by histone deacetylase inhibitors in human carcinoma cells. The Journal of Antibiotics 2000, 53:1191-1200.
42. Rosato R.R., Grant S. Histone deacetylase inhibitors in cancer therapy. Cancer Biology and Therapy 2003, 2:30-37.
43. Richon V.M., Sandhoff T.W., Rifkind R.A., Marks P.A. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proceedings of the National Academy of Sciences 2000, 97:10014-10019.
44. Carew J.S., Giles F.J., Nawrocki S.T. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Letters 2008, 269:7-17.
45. Butler L.M., Zhou X., Xu W.S., Scher H.I., Rifkind R.A., Marks P.A., Richon V.M. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proceedings of the National Academy of Sciences 2002, 99:11700-11705.
46. Ruefli A.A., Ausserlechner M.J., Bernhard D., Sutton V.R., Tainton K.M., Kofler R., Smyth M.J., Johnstone R.W. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proceedings of the National Academy of Sciences 2001, 98:10833-10838.
47. Johnstone R.W., Ruefli A.A., Lowe S.W. Apoptosis-A Link between Cancer Genetics and Chemotherapy. Cell 2002, 108:153-164.
48. Acharya M.R., Sparreboom A., Venitz J., Figg W.D. Rational development of histone deacetylase inhibitors as anticancer agents: a review. Molecular Pharmacology 2005, 68:917-932.
49. Botrugno O.A., Santoro F., Minucci S. Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer. Cancer Letters 2009, 280:134-144.
50. Cang S., Ma Y., Liu D. New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer. Journal of Hematology and Oncology 2009, 2:22-33.
51. Drummond D.C., Noble C.O., Kirpotin D.B., Guo Z., Scott G.K., Benz C.C. Clinical development of histone deacetylase inhibitors as anticancer agents. Annual Review of Pharmacology and Toxicology 2005, 45:495-528.
52. Ezzeldin H.H., Diasio R.B. Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs 2009, 69:1911-1934.
53. Garcia-Manero G., Issa J.P. Histone deacetylase inhibitors: a review of their clinical status as antineoplastic agents. Cancer Investigation 2005, 23:635-642.
54. Johnstone R.W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nature Reviews Drug Discovery 2002, 1:287-299.
55. Lee M.J., Kim Y.S., Kummar S., Giaccone G., Trepel J.B. Histone deacetylase inhibitors in cancer therapy. Current Opinion in Oncology 2008, 20:639.
56. Marchion D., Munster P. Development of histone deacetylase inhibitors for cancer treatment. Expert Review of Anticancer Therapy 2007, 7:583-598.
57. Marks P. Discovery and development of SAHA as an anticancer agent. Oncogene 2007, 26:1351-1356.
58. Marks P.A., Richon V.M., Breslow R., Rifkind R.A. Histone deacetylase inhibitors as new cancer drugs. Current Opinion in Oncology 2001, 13:477.
59. McLaughlin F., La Thangue N.B. Histone deacetylase inhibitors open new doors in cancer therapy. Biochemical Pharmacology 2004, 68:1139-1144.
60. Muller S., Kramer O.H. Inhibitors of HDACs - effective drugs against cancer?. Current Cancer Drug Targets 2010, 10:210-228.
61. Takai N., Narahara H. Preclinical studies of chemotherapy using histone deacetylase inhibitors in endometrial cancer. Obstetrics and Gynecology International 2010, 2010:1-8.
62. Prince H.M., Bishton M.J., Harrison S.J. Clinical studies of histone deacetylase inhibitors. Clinical Cancer Research 2009, 15:3958-3969.
63. Ramalingam S.S., Parise R.A., Ramananthan R.K., Lagattuta T.F., Musguire L.A., Stoller R.G., Potter D.M., Argiris A.E., Zwiebel J.A., Egorin M.J. Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clinical Cancer Research 2007, 13:3605-3610.
64. Glaser K.B. HDAC inhibitors: clinical update and mechanism-based potential. Biochemical Pharmacology 2007, 74:659-671.
65. Marks P., Xu W.S. Histone deacetylase inhibitors: potential in cancer therapy. Journal of Cellular Biochemistry 2009, 107:600-608.
66. Cashen A., Juckett M., Jumonville A., Litzow M., Flynn P., Eckardt J., LaPlant B., Laumann K., Erlichman C., DiPersio J. Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS). Annals of Hematology 2011, 1-6.
67. Giaccone G., Rajan A., Berman A., Kelly R.J., Szabo E., Lopez-Chavez A., Trepel J., Lee M.J., Cao L., Espinoza-Delgado I. Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. Journal of Clinical Oncology 2011, 29:2052-2059.
68. Gimsing P., Hansen M., Knudsen L.M., Knoblauch P., Christensen I.J., Ooi C.E., Buhl-Jensen P. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. European Journal of Haematology 2008, 81:170-176.
69. Mackay H.J., Hirte H., Colgan T., Covens A., MacAlpine K., Grenci P., Wang L., Mason J., Pham P.A., Tsao M.S. Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours. European Journal of Cancer 2010, 46:1573-1579.
70. Ramalingam S.S., Belani C.P., Ruel C., Frankel P., Gitlitz B., Koczywas M., Espinoza-Delgado I., Gandara D. Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. Journal of Thoracic Oncology 2009, 4:97.
71. Steele N.L., Plumb J.A., Vidal L., Tjørnelund J., Knoblauch P., Rasmussen A., Ooi C.E., Buhl-Jensen P., Brown R., Evans T.R.J. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clinical Cancer Research 2008, 14:804-810.
72. Olsen E.A., Kim Y.H., Kuzel T.M., Pacheco T.R., Foss F.M., Parker S., Frankel S.R., Chen C., Ricker J.L., Arduino J.M. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. Journal of Clinical Oncology 2007, 25:3109-3115.
73. Duvic M., Talpur R., Ni X., Zhang C., Hazarika P., Kelly C., Chiao J.H., Reilly J.F., Ricker J.L., Richon V.M. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007, 109:31-39.
74. Piekarz R., Frye R., Wright J., Figg W., Allen S., Kirschbaum M., Zain J., Hutchins L., Showe L., Fojo T. Update of the NCI multiinstitutional phase II trial of romidepsin, FK228, for patients with cutaneous or peripheral T-cell lymphoma. Journal of Clinical Oncology 2007, 25:8027.
75. Undevia S., Janisch L., Schilsky R., Loury D., Balasubramanian S., Mani C., Sirisawad M., Buggy J., Miller R., Ratain M. Phase I study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the histone deacetylase inhibitor (HDACi) PCI-24781. Journal of Clinical Oncology 2008, 26:14514S.
76. Fong P., Settatree S., Sinha R., Hardcastle A., Hellemans P., Arts J., Brown K., Janicot M., Aherne W., De Bono J. A first-in-man phase I study of R306465, a histone deacetylase (HDAC) inhibitor exploring pharmacokinetics (PK) and pharmacodynamics (PD) utilizing an electrochemiluminescent immunoassay in patients (p) with advanced tumours. Journal of Clinical Oncology 2007, 25:3578.
77. Prince H., George D., Patnaik A., Mita M., Dugan M., Butterfoss D., Masson E., Culver K., Burris H., Beck J. Phase I study of oral LBH589, a novel deacetylase (DAC) inhibitor in advanced solid tumors and non-hodgkin's lymphoma. Journal of Clinical Oncology 2007, 25:3500.
78. Sharma S., Vogelzang N., Beck J., Patnaik A., Mita M., Dugan M., Hwang A., Masson E., Culver K., Prince H. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of LBH589, a novel deacetylase (DAC) inhibitor given intravenously on a new once weekly schedule. Journal of Clinical Oncology 2007, 25:14019.
79. Yeo W., Lim R., Ma B., Hui P., Chan L., Mo F., Yu S., Ho S., Koh J., Chan A. A phase I/II study of belinostat (PXD101) in patients with unresectable hepatocellular carcinoma. Journal of Clinical Oncology 2007, 25:15081.
80. Grant C., Rahman F., Piekarz R., Peer C., Frye R., Robey R.W., Gardner E.R., Figg W.D., Bates S.E. Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Review of Anticancer Therapy 2010, 10:997-1008.
81. Rangwala S., Zhang C., Duvic M. HDAC inhibitors for the treatment of cutaneous T-cell lymphomas. Future 2012, 4:471-486.
82. Kim M.S., Blake M., Baek J.H., Kohlhagen G., Pommier Y., Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Research 2003, 63:7291-7300.
83. Nelson S.M., Ferguson L.R., Denny W.A. DNA and the chromosome - varied targets for chemotherapy. Cell and Chromosome 2004, 3:2-28.
84. Whang Y.M., Choi E.J., Seo J.H., Kim J.S., Yoo Y.D., Kim Y.H. Hyperacetylation enhances the growth-inhibitory effect of all-trans retinoic acid by the restoration of retinoic acid receptor β expression in head and neck squamous carcinoma (HNSCC) cells. Cancer Chemotherapy and Pharmacology 2005, 56:543-555.
85. Zhu W.G., Lakshmanan R.R., Beal M.D., Otterson G.A. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Research 2001, 61:1327-1333.
86. Mehnert J.M., Kelly W.K. Histone deacetylase inhibitors: biology and mechanism of action. The Cancer Journal 2007, 13:2329.
87. Xu W., Parmigiani R., Marks P. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007, 26:5541-5552.
88. Jin K.L., Park J.Y., Noh E.J., Hoe K.L., Lee J.H., Kim J.H., Nam J.H. The effect of combined treatment with cisplatin and histone deacetylase inhibitors on HeLa cells. Journal of Gynecologic Oncology 2010, 21:262-268.
89. Blumenschein G.R., Kies M.S., Papadimitrakopoulou V.A., Lu C., Kumar A.J., Ricker J.L., Chiao J.H., Chen C., Frankel S.R. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza™, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Investigational New Drugs 2008, 26:81-87.
90. Bolden J.E., Peart M.J., Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nature Reviews Drug Discovery 2006, 5:769-784.
91. Ramalingam S.S., Maitland M.L., Frankel P., Argiris A.E., Koczywas M., Gitlitz B., Thomas S., Espinoza-Delgado I., Vokes E.E., Gandara D.R. Carboplatin and paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. Journal of Clinical Oncology 2010, 28:56-62.
92. Shen J., Huang C., Jiang L., Gao F., Wang Z., Zhang Y., Bai J., Zhou H., Chen Q. Enhancement of cisplatin induced apoptosis by suberoylanilide hydroxamic acid in human oral squamous cell carcinoma cell lines. Biochemical Pharmacology 2007, 73:1901-1909.
93. Suzuki M., Endo M., Shinohara F., Echigo S., Rikiishi H. Enhancement of cisplatin cytotoxicity by SAHA involves endoplasmic reticulum stress-mediated apoptosis in oral squamous cell carcinoma cells. Cancer Chemotherapy and Pharmacology 2009, 64:1115-1122.
94. Rikiishi H., Shinohara F., Sato T., Sato Y., Suzuki M., Echigo S. Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid. International Journal of Oncology 2007, 30:1181-1188.
95. Sato T., Suzuki M., Sato Y., Echigo S., Rikiishi H. Sequence-dependent interaction between cisplatin and histone deacetylase inhibitors in human oral squamous cell carcinoma cells. International Journal of Oncology 2006, 28:1233-1241.
96. Vandermeers F., Hubert P., Delvenne P., Mascaux C., Grigoriu B., Burny A., Scherpereel A., Willems L. Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma. Clinical Cancer Research 2009, 15:2818-2828.
97. Erlich R.B., Rickwood D., Coman W.B., Saunders N.A., Guminski A. Valproic acid as a therapeutic agent for head and neck squamous cell carcinomas. Cancer Chemotherapy and Pharmacology 2009, 63:381-389.
98. Bloemink M., Heetebrij R., Inagaki K., Kidani Y., Reedijk J. Reactions of unsymmetrically substituted derivatives of cisplatin with short oligodeoxynucleotides containing a-GpG-sequence. H-bonding interactions in pGpG moieties cross-linked by an asymmetric platinum complex enhancing the formation of one geometrical isomer. Inorganic Chemistry 1992, 31:4656-4661.
99. Valentini A., Gravina P., Federici G., Bernardini S. Valproic acid induces apoptosis, p16INK4A upregulation and sensitization to chemotherapy in human melanoma cells. Cancer Biology and Therapy 2007, 6:185.
100. Ozaki K., Kishikawa F., Tanaka M., Sakamoto T., Tanimura S., Kohno M. Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs. Cancer Science 2008, 99:376-384.
101. Yoon C.Y., Park M.J., Lee J.S., Lee S.C., Oh J.J., Park H., Chung C.W., Abdullajanov M.M., Jeong S.J., Hong S.K. The histone deacetylase inhibitor trichostatin a synergistically resensitizes a cisplatin resistant human bladder cancer cell line. The Journal of Urology 2011, 185:1102-1111.
102. Wang R.H., Liu C., Avramis V.I., Berndt N. Protein phosphatase 1alpha-mediated stimulation of apoptosis is associated with dephosphorylation of the retinoblastoma protein. Oncogene 2001, 20:6111-6122.
103. Bali P., Pranpat M., Swaby R., Fiskus W., Yamaguchi H., Balasis M., Rocha K., Wang H.G., Richon V., Bhalla K. Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of her-2. Clinical Cancer Research 2005, 11:6382-6389.
104. DeGeest E.M., Hartenbach R., Baergen Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic Oncology Group study. Journal of Clinical Oncology 2003, 21:3194-3200.
105. Choi J.H., Kwon H.J., Yoon B.I.I., Kim J.H., Han S.U., Joo H.J., Kim D.Y. Expression profile of histone deacetylase 1 in gastric cancer tissues. Cancer Science 2001, 92:1300-1304.
106. Fritzsche F., Weichert W., Röske A., Gekeler V., Beckers T., Stephan C., Jung K., Scholman K., Denkert C., Dietel M. Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. BMC Cancer 2008, 8:381-391.
107. Ishihama K., Yamakawa M., Semba S., Takeda H., Kawata S., Kimura S., Kimura W. Expression of HDAC1 and CBP/p300 in human colorectal carcinomas. Journal of Clinical Pathology 2007, 60:1205-1210.
108. Jin K.L., Pak J.H., Park J.Y., Choi W.H., Lee J.Y., Kim J.H., Nam J.H. Expression profile of histone deacetylases 1, 2 and 3 in ovarian cancer tissues. Journal of Gynecologic Oncology 2008, 19:185-190.
109. Khabele D., Son D.S., Parl A.K., Goldberg G.L., Augenlicht L.H., Mariadason J.M., Rice V.M. Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth. Cancer Biology and Therapy 2007, 6:795-801.
110. Waltregny D., North B., Van Mellaert F., De Leval J., Verdin E., Castronovo V. Screening of histone deacetylases (HDAC) expression in human prostate cancer reveals distinct class I HDAC profiles between epithelial and stromal cells. European Journal of Histochemistry 2009, 48:273-290.
111. Wang L., Zou X., Berger A.D., Twiss C., Peng Y., Li Y., Chiu J., Guo H., Satagopan J., Wilton A. Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA. American Journal of Translational Research 2009, 1:62-71.
112. Zhu P., Martin E., Mengwasser J., Schlag P., Janssen K.P., Göttlicher M. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 2004, 5:455-463.
113. Tavera-Mendoza L.E., Quach T.D., Dabbas B., Hudon J., Liao X., Palijan A., Gleason J.L., White J.H. Incorporation of histone deacetylase inhibition into the structure of a nuclear receptor agonist. Proceedings of the National Academy of Sciences 2008, 105:8250.
114. Y. Chen, Hydroxamic acid derivatives, WO Patent 2,010,085,377, 2010.
115. Griffith D., Morgan M.P., Marmion C.J. A novel anti-cancer bifunctional platinum drug candidate with dual DNA binding and histone deacetylase inhibitory activity. Chemical Communications 2009, 6(105):6735-6737.
116. Griffith D.M., Duff B., Suponitsky K., Kavanagh K., Morgan M.P., Egan D., Marmion C.J. Novel trans-platinum complexes of the histone deacetylase inhibitor valproic acid; synthesis, in vitro cytotoxicity and mutagenicity. Journal of Inorganic Biochemistry 2011, 793-799.
117. C.J. Marmion, D. Griffith, Metal complexes having dual histone deacetylase inhibitory and DNA-binding activity, WO Patent WO/2011/006,908, 2011.
118. Dokmanovic M., Perez G., Xu W., Ngo L., Clarke C., Parmigiani R.B., Marks P.A. Histone deacetylase inhibitors selectively suppress expression of HDAC7. Molecular Cancer Therapeutics 2007, 6:2525-2534.
119. Lee J.H., Choy M., Ngo L., Foster S., Marks P.A. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proceedings of the National Academy of Sciences 2010, 107:14639-14644.
120. Brabec V., Griffith D.M., Kisova A., Kostrhunova H., Zerzankova L., Marmion C.J., Kasparkova J. Valuable insight into the anticancer activity of the platinum-histone deacetylase inhibitor conjugate, cis-[Pt (NH3) 2malSAHA-2H)]. Molecular Pharmaceutics 2012, 9:1990-1999.